Raymond Purves Laboratory, Institute of Bone and Joint Research, Kolling Institute of Medical Research, The Royal North Shore Hospital, Level 10, Kolling Building B6, St. Leonards, NSW 2065, Australia.
Histochem Cell Biol. 2010 Sep;134(3):251-63. doi: 10.1007/s00418-010-0730-x. Epub 2010 Aug 6.
We undertook a comparative immunolocalisation study on type II collagen, aggrecan and perlecan in a number of 12- to 14-week-old human foetal and postnatal (7-19 months) ovine joints including finger, toe, knee, elbow, hip and shoulder. This demonstrated that perlecan followed a virtually identical immunolocalisation pattern to that of type II collagen in the foetal tissues, but a slightly divergent localisation pattern in adult tissues. Aggrecan was also localised in the cartilaginous joint tissues, which were clearly delineated by toluidine blue staining and the type II collagen immunolocalisations. It was also present in the capsular joint tissues and in ligaments and tendons in the joint, which stained poorly or not at all with toluidine blue. In higher power microscopic views, antibodies to perlecan also stained small blood vessels in the synovial lining tissues of the joint capsule; however, this was not discernable in low power macroscopic views where the immunolocalisation of perlecan to pericellular regions of cells within the cartilaginous rudiments was a predominant feature. Perlecan was also evident in small blood vessels in stromal connective tissues associated with the cartilage rudiments and with occasional nerves in the vicinity of the joint tissues. Perlecan was expressed by rounded cells in the enthesis attachment points of tendons to bone and in rounded cells in the inner third of the meniscus, which stained prominently with type II collagen and aggrecan identifying the chondrogenic background of these cells and local compressive loads. Flattened cells within the tendon and in the surface laminas of articular cartilages and the meniscus did not express perlecan. Collected evidence presented herein, therefore, indicates that besides being a basement membrane component, perlecan is also a marker of chondrogenic cells in prenatal cartilages. In postnatal cartilages, perlecan displayed a pericellular localisation pattern rather than the territorial or interterritorial localisation it displayed in foetal cartilages. This may reflect processing of extracellular perlecan presumably as a consequence of intrinsic biomechanical loading on these tissues or to divergent functions for perlecan and type II collagen in adult compared to prenatal tissues.
我们对 12 至 14 周龄人类胎儿和产后(7 至 19 个月)羊关节(包括手指、脚趾、膝盖、肘部、臀部和肩部)中的 II 型胶原、聚集蛋白聚糖和 perlecan 进行了比较免疫定位研究。这表明 perlecan 在胎儿组织中的免疫定位模式与 II 型胶原几乎完全相同,但在成人组织中的定位模式略有不同。聚集蛋白聚糖也存在于软骨关节组织中,这些组织通过甲苯胺蓝染色和 II 型胶原免疫定位清晰划定。它也存在于关节囊组织中的关节和韧带和肌腱中,这些组织用甲苯胺蓝染色染色不良或根本不染色。在更高的显微镜视图中,针对 perlecan 的抗体也染色了关节囊滑膜衬里组织中的小血管;然而,在低倍宏观视图中,perlecan 对软骨原基细胞周围细胞的细胞定位是主要特征,因此无法识别。perlecan 也存在于软骨原基相关的基质结缔组织中的小血管和关节组织附近的偶尔神经中。perlecan 存在于肌腱与骨的附着点的圆形细胞中和半月板内三分之一的圆形细胞中,这些细胞用 II 型胶原和聚集蛋白聚糖染色明显,鉴定了这些细胞的软骨生成背景和局部压缩载荷。在肌腱的附着点和半月板的圆形细胞中和半月板的内三分之一中存在扁平细胞,不表达 perlecan。因此,本文提出的证据表明,除了作为基底膜成分外,perlecan 也是产前软骨中成软骨细胞的标志物。在产后软骨中,perlecan 显示出细胞周定位模式,而不是它在胎儿软骨中显示的区域或区域间定位模式。这可能反映了细胞外 perlecan 的处理,推测是由于这些组织的内在生物力学载荷或与成人相比,perlecan 和 II 型胶原在成人组织中的功能不同所致。